p-AKT和HIF-1α蛋白表达水平与新辅助化疗治疗乳腺癌疗效的相关性分析  

Analysis of the relationship between the expression of p-AKT and HIF-1α protein and the response of breast cancer to neoadjuvant chemotherapy

作　　者：郑克思[1] 陈聪[1] 吴元肇 张筱骅[2] 

机构地区：[1]温州医科大学温州市第三临床学院(温州市人民医院)肿瘤外科,浙江温州325000 [2]温州医科大学附属第一医院肿瘤外科,浙江温州325000

出　　处：《中国生化药物杂志》2017年第7期259-260,263,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的研究分析磷酸化蛋白激酶（p-AKT）和低氧诱导因子-1α（HIF-1α）蛋白表达与乳腺癌新辅助化疗疗效之间的关系。方法对温州市人民医院2014年1月~2016年12月收治的接受4~6个周期方案为TEC新辅助化疗的70例乳腺癌患者的资料进行回顾性研究。用免疫组织化学方法检测新辅助化疗前肿瘤病灶p-AKT和HIF-1α蛋白的表达情况,用术后病理评价新辅助化疗疗效,病理学反应级别为G4、病理完全缓解（PCR）则认为化疗有效。通过χ~2检验、Fisher确切概率法探讨上述指标与新辅助化疗疗效之间的相关性。结果 70例患者中新辅助化疗有效率为52.9%（37/70）,其中PCR占21.4%（15/70）。p-AKT和HIF-1α的阳性表达率分别为64.3%（45/70）和61.4%（43/70）。χ~2检验、Fisher确切概率法分析表明p-AKT和HIF-1α均与新辅助化疗疗效相关（P=0.002,P=0.035）,与获得PCR也相关（P=0.001,P=0.015）。结论化疗前,p-AKT和HIF-1α蛋白阳性表达状态降低患者对于相关乳腺癌治疗药物的敏感性,阴性表达患者能更多地从化疗中获益。Objective To study the relationship between the expression of p-AKT and HIF-1αprotein and the response of breast cancer to neoadjuvant chemotherapy. Methods A retrospective study was performed on 70 cases of breast cancer patients receiving 4-6 cycles of TEC neoadjuvant chemotherapy in Wenzhou people＇s hospital from January 2014 to December 2016. Immunohistochemistry was applied to the detection of p-AKT and HIF-1αexpression before chemotherapy. Neoadjuvant chemotherapy response was evaluated according to the postoperative pathology. Pathological response to G4 or complete response were considered to be response efficaciously. Chi-square test and Fisher＇s test were applied to analyze the correlation between these index and the efficacy of neoadjuvant chemotherapy. Results The response rate of neoadjuvant chemotherapy was 52. 9%（ 37/70） among the 70 cases,among which the pathological complete response（ PCR） was 21. 4%（ 15/70）. The positive expression of p-AKT and HIF-1α were 64. 3%（ 45/70）and 61. 4%（ 43/70） respectively. Statistical analysis shows that p-AKT and HIF-1α expression were associated with the response of neoadjuvant chemotherapy of breast cancer（ P = 0. 002,P = 0. 035）,and also associated with the PCR（ P = 0. 001,P = 0. 015）. Conclusion p-AKT and HIF-1αexpression in breast cancer reduce the sensitivity of neoadjuvant chemotherapy to breast cancer. Patient with negative expression may benefit more from neoadjuvant chemotherapy.

关 键 词：磷酸化蛋白激酶 低氧诱导因子-1Α 新辅助化疗 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]